Reviews in Experimental Pharmacology and Drug Discovery 2023: Pharmacological management of noncommunicable diseases

Ali Sharif ^1* Virginia Flores-Morales ^2* Hanan Farouk Aly ³

• ¹ Lahore College for Women University, Lahore, Punjab, Pakistan
• ² Unidad Academica de Ciencias Quimicas, Universidad Autonoma de Zacatecas, Zacatecas, Mexico
• ³ National Research Centre (Egypt), Cairo, Cairo, Egypt

ingredients from traditional medicines to the search of chemical libraries for specific molecules with predicted kinetic properties. The aim of the current issue was to throw light on the Pharmacological advancements in managing noncommunicable diseases.Current issue provides insight into the evaluation of mirabegron which is a β3-adrenergic agonist as a medical expulsive therapy for ureteral stones in adult. The study concluded with the opinion that mirabegron appeared to a better treatment option for stones ≤4-6 mm especially distal ureteral stones against placebo. Similarly, Catheterrelated bladder discomfort (CRBD) secondary to the use of large-diameter urinary catheters particularly after urological surgeries can lead to increased frequency in urination, accompanied or not by involuntary loss of urine.Nefopam, a centrally acting analgesic with anticholinergic properties was evaluated for managing postoperative CRBD. Nefopam administration mitigated the frequency and severity of early postoperative CRBD without causing evident side effects. Ondansetron was validated for its use in pregnancy associated morning sickness, but study lacks the clarity in identification and analysis of efficacy and safety. Similarly, ondansetron has been a gold standard in treating chemotherapy induced nausea and vomiting. The impact on safety and patient's lives can be elaborated in a better way. Amphetamine and its derivatives have been employed in the treatment of attention deficit hyperactive syndrome since a long time. The study was concluded with emphasis on the importance of recognizing potential side effects and addiction risks. Tyrosine kinase inhibitors one of the main stay in cancer therapy were proposed to have glycemic control properties. The results emerged as a mixture of improved glycemic control with some tyrosine kinase inhibitors whereas clinically insignificant hyperglycemia control with some other tyrosine kinase inhibitors. The repurposing strategies of these inhibitors towards managing diabetes mellitus needs further exploration.Dr. Ali Sharif Dra. Virginia Flores Morales